Journal Home
Search for

Volume 49, Issue 6, Pages 899-907 (December 2008)


View previous. 9 of 38 View next.

The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism

Ya-Hui Tsai1, Wan-Fen Kuang2, Tsai-Yi Lu1, Jia-Horng Kao2, Ming-Yang Lai3, Chun-Jen Liu3, Pei-Jer Chen3, Lih-Hwa Hwang12Corresponding Author Informationemail address

Received 9 January 2008; received in revised form 13 May 2008; accepted 26 June 2008. published online 16 September 2008.

Background/Aims

Patients infected with hepatitis C virus (HCV) genotype 2 or 3 usually respond better to interferon (IFN) treatment than those infected with genotype 1. In this study, we investigated whether the non-structural 5A protein (NS5A) of HCV genotypes 1 and 2 (1b-NS5A and 2a-NS5A, respectively) exerted differential counteractivities against IFN treatment.

Methods

We compared the inhibitory effects of 1b-NS5As and 2a-NS5As on IFN activity. We also investigated the replication inhibition of HCV subgenomic replicons containing 1b-NS5A or 2a-NS5A in response to IFN treatment.

Results

1b-NS5As exerted more profound inhibitory effects on IFN activity than 2a-NS5As. The replication of the 2a-NS5A-containing replicons was more sensitive to IFN treatment than that of the 1b-NS5A-containing replicons. Deletion of the interferon sensitivity-determining region/protein kinase R-binding domain (PKR-BD), the V3 domain, or the C-terminus region of NS5A significantly abrogated its anti-IFN activity. Domain swapping between 1b-NS5A and 2a-NS5A in the V3 domain and/or the C-terminus region resulted in a transfer of their anti-IFN activity.

Conclusions

1b-NS5As exert higher magnitudes of IFN antagonism than do 2a-NS5As. The V3 and the C-terminus regions are responsible for the differential anti-IFN effects. This phenomenon may partly explain the genotype-linked differences in the response of HCV to IFN treatment.

Associate Editor: J.G. McHutchison

1 Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan

2 Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan

3 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan

Corresponding Author InformationCorresponding author. Tel.: +886 2 28267114; fax: +886 2 28212880.

 The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the materials involved either in the past or present and they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00560-6

doi:10.1016/j.jhep.2008.06.030


View previous. 9 of 38 View next.